IQVIA Hldgs Analyst Ratings
HSBC Downgrades IQVIA Holdings(IQV.US) to Hold Rating, Cuts Target Price to $160
HSBC Downgrades IQVIA to Hold From Buy, Adjusts Price Target to $160 From $260
Jefferies Maintains IQVIA Holdings(IQV.US) With Hold Rating, Cuts Target Price to $165
BofA Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $190
Resilience and Growth: IQVIA Holdings' Buy Rating Amid RDS Challenges and TAS Strength
Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $216
IQVIA Holdings Price Target Cut to $216.00/Share From $263.00 by Truist Securities
IQVIA Holdings Is Maintained at Buy by Truist Securities
Barclays Downgrades IQVIA Holdings(IQV.US) to Hold Rating, Cuts Target Price to $170
Mizuho Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $210
Stifel Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $211
IQVIA Hldgs Analyst Ratings
Goldman Sachs Adjusts IQVIA Holdings Price Target to $200 From $230, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Nanobiotix (NBTX) and IQVIA Holdings (IQV)
Baird Maintains IQVIA Holdings(IQV.US) With Hold Rating, Cuts Target Price to $195
Baird Adjusts IQVIA Holdings Price Target to $195 From $220, Maintains Neutral Rating
Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating
Truist Financial Remains a Buy on IQVIA Holdings (IQV)
Mizuho Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $242